SCHEMBL5455162

SCHEMBL5455162

CC1CCc2c(sc(NC(=O)Oc3ccccc3)c2C(N)=O)C1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.72
DUSP3 P51452 1/20 0.72
PTPN5 P54829 1/20 0.72
PTPN11 Q06124 1/20 0.72
POLB P06746 1/20 0.67
ALDH1A1 P00352 2/20 0.61
KDM4E B2RXH2 2/20 0.61
THRB P10828 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.60
PDE4B Q07343 2/20 0.60
PDE4D Q08499 1/20 0.60
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
RXFP1 Q9HBX9 1/20 0.58
TP53 P04637 2/20 0.57
CNR2 P34972 1/20 0.56
TNIK Q9UKE5 1/20 0.56
ATM Q13315 1/20 0.55
REV1 Q9UBZ9 1/20 0.54
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10143922 0.84 MAPT (1.00) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL2182372 0.84 TP53 (0.80) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL8288667 0.82 MAPT (1.00) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL3914076 0.79 MAPT (0.73) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL3916246 0.79 MAPT (0.78) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL5451008 0.78 CFTR (0.59) MAPTALDH1A1NPC1RAB9ACNR2
SCHEMBL21346818 0.78 FLT3 (0.70) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL3916303 0.77 REV1 (0.79) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL8289434 0.77 RXFP1 (0.75) MAPTDUSP3PTPN5PTPN11POLB
SCHEMBL3922433 0.77 MEN1 (0.82) MAPTDUSP3PTPN5PTPN11POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885DUSP3 110/4885PTPN5 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.